11C-JHU75528: A radiotracer for PET imaging of CB1 cannabinoid receptors

Journal of Nuclear Medicine

Volumn 47, Issue 10, 2006, Pages 1689-1696

  Horti, Andrew G ^a,b   Fan, Hong ^a   Kuwabara, Hiroto ^a   Hilton, John ^a   Ravert, Hayden T ^a   Holt, Daniel P ^a   Alexander, Mohab ^a   Kumar, Anil ^a   Rahmim, Arman ^a   Scheffel, Ursula ^a   Wong, Dean F ^a   Dannals, Robert F ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

11C JHU75528; Cannabinoid receptor; PET

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; [4 CYANO 1 (2,4 DICHLOROPHENYL) 5 (4 METHOXYPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE] C 11; CANNABINOID 1 RECEPTOR; CYTISINE; JHU 75528; KETANSERIN; NALOXONE; NALTRINDOLE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; RIMONABANT; SPIPERONE; UNCLASSIFIED DRUG; 4 CYANO 1 (2,4 DICHLOROPHENYL) 5 (4 METHOXYPHENYL) N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 4-CYANO-1-(2,4-DICHLOROPHENYL)-5-(4-METHOXYPHENYL)-N-(PIPERIDIN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE; CARBON; LIGAND; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BINDING AFFINITY; BRAIN REGION; BRAIN STEM; CONTROLLED STUDY; CORPUS STRIATUM; HYDROPHILICITY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; RADIOACTIVITY; ANIMAL; BLOOD BRAIN BARRIER; BRAIN; DRUG ANTAGONISM; METABOLISM; PAPIO; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN STEM; CARBON RADIOISOTOPES; LIGANDS; MALE; MICE; PAPIO; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1; TISSUE DISTRIBUTION;

EID: 34547486580     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.
2. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005;7:E625-E654.
3. Gambi F, De Berardis D, Sepede G, et al. Cannabinoid receptors and their relationships with neuropsychiatric disorders. Int J Immunopathol Pharmacol. 2005;18:15-19.
4. Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol. 2005;16:315-331.
5. De Vries TJ, Schoffelmeer AN. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci. 2005;26:420-426.
6. Le Foll B, Goldberg SR. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci. 2005;26:287-293.
7. Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets. 2005;6:215-223.
8. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244.
9. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397.
10. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-508.
11. 9- THC. Pharmacol Biochem Behav. 1991;40:503-507.
12. 18F] SR144385: a selective radioligand for positron emission tomographic studies of brain cannabinoid receptors. J Labelled Compds Radiopharm. 1999;42:589-596.
13. 18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl Med Biol. 2000;27:757-762.
14. Mathews WB, Scheffel U, Rauseo PA, et al. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nucl Med Biol. 2002;29:671-677.
15. Katoch-Rouse R, Pavlova OA, Caulder T, Hoffman AF, Mukhin AG, Horti AG. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. J Med Chem. 2003;46:642-645.
16. Willis PG, Katoch-Rouse R, Horti AG. Regioselective F-18 radiolabeling of AM694, a CB1 cannabinoid receptor ligand. J Labelled Compds Radiopharm. 2003;46:799-804.
17. 18F]fluorination: a PET radiotracer for studying CB1 cannabinoid receptors. J Labelled Compds Radiopharm. 2003;46:93-98.
18. Gatley SJ, Gifford AN, Ding Y-S, et al. Development of PET and SPECT radioligands for cannabinoid receptors. In: Makriyannis A, Biegel D, eds. Drug Discovery Strategies and Methods. New York, NY: Marcel Dekker, Inc.; 2004:129-146.
19. Gatley SJ, Lan R, Volkow ND, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70:417-423.
20. 18F]AM5144 and related pyrazole compounds. Nucl Med Biol. 2005;32:361-366.
21. 9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biol Psychiatry. 2004;55:904-915.
22. Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. J Med Chem. 2005;48:5813-5822.
23. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363-375.
24. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376-389.
25. Katoch-Rouse R, Chefer SI, Pavlova OA, et al. Development of C-11-NIDA-41020: a potential radiotracer for studying cerebral cannabinoid receptors (CB1) by PET. Presented at: IX Symposium on the Medical Applications of Cyclotrons; May 25-28, 2002; Turku, Finland.
26. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003;8:927-933.
27. Shire D, Calandra B, Bouaboula M, et al. Cannabinoid receptor interactions with the antagonists SR141716A and SR144528. Life Sci. 1999;65:627-635.
28. 11C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. J Labelled Compds Radiopharm. In press.
29. 18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects. J Cereb Blood Flow Metab. 1993;13:43-56.
30. 11C]WIN 35, 428. Synapse. 1993;15:130-142.
31. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096-1112.
32. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630.
33. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299-318.
34. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A. 1990;87:1932-1936.
35. Di Marco A, Yao D, Laufer R. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur J Biochem. 2003;270:3768-3777.
36. - from blood to brain in dogs. J Appl Physiol. 1983;54:989-996.
37. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:355-360.
38. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci. 2004;96:376-381.
39. 35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry. 2004;9:184-190.
40. Vinod KY, Arango V, Xie S, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 2005;57:480-486.